356P CD80 tumour-expression predicts benefits from capecitabine in the BILCAP phase III randomized adjuvant trial
Title:
356P CD80 tumour-expression predicts benefits from capecitabine in the BILCAP phase III randomized adjuvant trial
Author:
Rofei, M. Formica, V. Fassan, M. Rae, C. Crolley, V.E. Nixon, C. Lopez, M.A.M. Ellis, M. Greaves, J. Marco, S. Morelli, C. Tesini, G. Bridgewater, J.A. Primrose, J.N. Braconi, C.